OCR Guidance on COVID-19 Patients and Antibody Donation

Daniel Lebovic
Published: June 16, 2020•Last Updated: July 15, 2024•Read Time: 3 min

Summary

HIPAA permits using PHI to identify recovered COVID-19 patients for antibody donation outreach as a population-based healthcare operations activity, but providers must limit disclosures to the minimum necessary, avoid marketing communications, and may not steer donors to specific blood or plasma centers if there is direct or indirect payment. OCR clarified these restrictions on June 12, 2020, guiding compliant outreach and case management efforts.

Track and Manage Your Compliance
The Guard compliance dashboard
Unlock the Secrets to Effective Risk Assessments
Understanding and Applying Risk Assessment Procedures in Healthcare Compliance guide cover
OCR Guidance

On June 12, 2020, the Department of Health and Human Services’ (HHS) Office for Civil Rights (OCR) issued guidance on whether or not a healthcare provider may use protected health information (PHI) to identify and contact patients who have recovered from COVID-19. The OCR guidance states that HIPAA permits such use of PHI to identify recovered patients, to provide them with information as to how they can donate COVID-19 antibodies to help treat other COVID patients. Circumstances under which former COVID-19 patients may be contacted are discussed below.

OCR Guidance: When Can Providers Use PHI to Identify Former COVID-19 Patients?

According to the new OCR guidance, healthcare providers may use PHI to contact patients who have recovered from COVID-19, so that they may donate their blood and plasma. Blood and plasma from recovered patients contain antibodies to the virus causing COVID-19; it is hoped such donations can help treat patients who currently have the virus.

Do you have an effective HIPAA compliance program?
Find out now by completing the HIPAA compliance checklist.

The HIPAA Privacy Rule allows HIPAA covered entities, including healthcare providers, to use or disclose PHI for treatment, payment, and healthcare operations, without written patient authorization. “Healthcare operations” include, among other things, population-based activities that are related to improving health, case management, and care coordination activities that do not meet the definition of treatment (i.e., where such activities are not connected to the care of a specific patient). Population-based activities and research, while not “treatment” themselves, are used to develop or modify treatment protocols. 

According to the OCR guidance, the use of PHI to identify and contact former COVID-19 patients is a “population-based” healthcare operations activity. This is because facilitating the supply of donated blood and plasma is expected to improve a provider’s ability to conduct case management, and develop treatment protocols, for patient populations that have or may become infected with COVID-19.

OCR Guidance: Restrictions on Providers’ Use of PHI to Identify Former COVID-19 Patients

When using or disclosing PHI for healthcare operations, including using PHI to identify and contact former COVID-19 patients, a healthcare provider must make reasonable efforts to limit the use or disclosure of PHI to the minimum necessary.

In addition, providers may contact identified former COVID-19 patients only to the extent that the contact does not involve marketing. Generally, the HIPAA Privacy Rule prohibits the use or disclosure of PHI for marketing purposes without a patient’s authorization.

Therefore, communications that inform or encourage patients who have recovered from COVID-19 to use any particular blood and plasma center(s) for such donations, would constitute marketing, unless the communication meets an exception to the definition of marketing. Under one exception to the definition, a provider is permitted to make such communication, provided that the provider receives no direct or indirect payment from, or on behalf of, the third party whose service is being described in the communication (i.e., a blood and plasma donation center).

HIPAA and State Privacy Compliance

Satisfy state and federal HIPAA laws with streamlined software.

Global CTAs Image

About the Author

Daniel Lebovic is the Corporate Legal Counsel and Content Editor at Compliancy Group. His extensive experience as a regulatory attorney, combined with his background as a legal writer, editor, and copy editor, uniquely qualifies him to translate healthcare regulations into easily digestible content that those with or without a legal background can understand.